Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes
More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)
Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
11/2005
11/03/2005WO2005000240A3 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
11/03/2005WO2004108070A3 Releasable polymeric conjugates based on aliphatic biodegradable linkers
11/03/2005WO2004103301A3 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
11/03/2005WO2004096131A3 Inhibitors of akt activity
11/03/2005WO2004087073A3 Treatment of demyelinating conditions
11/03/2005WO2004084827A3 Reduction of zinc-induced neurotoxic injury by blockade of nitric oxide synthesis
11/03/2005WO2004066915A3 Old-35, a gene associated with senescence and terminal cell differentiation, and uses thereof
11/03/2005US20050245605 Anhydrous silver dihydrogen citrate compositions
11/03/2005US20050245601 Treatment of diseases involving ErbB2 kinase overexpression
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245588 Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
11/03/2005US20050245581 3-(2-Cyanophenyl)-5-(2-methoxyphenyl)-1-phenyl-1,2-dihydropyridin-2-one; antagonists of AMPA and kainate receptors; neuroprotectants; neurodegenerative diseases; Alzheinmer's disease; antiepileptic agents; antispasmodic agents; anxiolytic agents; ddrug abuse; nervous sytem disorders; antihypoxic agents
11/03/2005US20050245565 Diamine derivatives
11/03/2005US20050245445 Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs
11/03/2005US20050244517 Combination of proton pump inhibitor and sleep aid
11/03/2005US20050244490 Dosing methods for beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
11/03/2005US20050244435 Comprises clostridial neurotoxin light chain domains; endopeptidases; vaccines; fusion proteins; for inhibiting exocytosis
11/03/2005US20050244386 Method of transplanting in a mammal and treating diabetes mellitus by administering a pseudo-islet like aggregate differentiated from a nestin-positive pancreatic stem cell
11/03/2005US20050244358 Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery
11/03/2005US20050242033 Extracorporeal pathogen reduction system
11/03/2005CA2564453A1 Peptide inhibitors of metalloproteinase activity
11/03/2005CA2564436A1 Use of chondroitin sulphate e (cs-e ) for the treatment of disease or conditions related to collagen fibril formation.
11/02/2005EP1591122A1 Method of administering bisphosphonates
11/02/2005EP1590668A2 Screeninig and treatment methods for prevention of preterm delivery
11/02/2005EP1590344A2 Anti-cancer medicaments
11/02/2005EP1590339A2 Chemical compounds
11/02/2005EP1590336A2 Substituted pyrazoles, compositions containing such compounds and methods of use
11/02/2005EP1590004A2 Improved thickened beverages for dysphagia
11/02/2005EP1590001A2 Method for in vivo regulation of cardiac muscle contractility
11/02/2005EP1589998A2 Uses of mammalian cytokine; related reagents
11/02/2005EP1589996A2 Anti-integrin alpha beta 3 antibody formulat ions and uses thereof
11/02/2005EP1589994A2 Composition and method for preventing or treating a virus infection
11/02/2005EP1589993A2 Combination therapy for treating protein deficiency disorders
11/02/2005EP1589987A1 Use of the cathelicidin ll-37 and derivatives thereof for wound healing
11/02/2005EP1589985A2 Methods and compositions in treating pain and painful disorders using 16386, 15402, 21165, 1423, 636, 12303, 21425, 27410, 38554, 38555, 55063, 57145, 59914, 94921, 16852, 33260, 58573, 30911, 85913, 14303, 16816, 17827 or 32620
11/02/2005EP1589981A2 Interferon antagonists useful for the treatment of interferon related diseases
11/02/2005EP1589969A2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
11/02/2005EP1589968A2 Quaternary antimuscarinic compounds for the treatment of bladder diseases
11/02/2005EP1589961A2 A therapeutic composition for the treatment of hiv-1 and hiv-2
11/02/2005EP1589946A2 Solution for nostril wash
11/02/2005EP1589943A2 Methods of treating lung diseases
11/02/2005EP1589933A2 Compositions and methods for the diagnosis and treatment of tumor
11/02/2005EP1589931A2 RNAi TARGETING OF VIRUSES
11/02/2005EP1589930A2 Combination therapy for anticoagulation
11/02/2005EP1589917A2 Methods of administering a dermatological agent to a subject
11/02/2005CN1692101A 4-oxoquinoline compounds and utilization thereof as HIV integrase inhibitors
11/02/2005CN1691963A Treatment of tnfalpha related disorders
11/02/2005CN1690077A Compositions for the therapy and diagnosis of prostate cancer and its uses
11/02/2005CN1690047A 9-substituted minocycline compounds
11/02/2005CN1225466C Sodium-hydrogen exchanger type 1 inhibitor (NHE-1)
11/02/2005CN1225233C Aqueous composition for bleaching keratin fibers instantaneously
11/01/2005US6960298 Mesoporous permeation layers for use on active electronic matrix devices
10/2005
10/27/2005WO2005100351A1 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR
10/27/2005WO2005100324A1 2- ( arylalkoxy ) -1- phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors
10/27/2005WO2005058248A3 A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor
10/27/2005WO2005048912A3 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
10/27/2005WO2005046567B1 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
10/27/2005WO2005044178A3 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
10/27/2005WO2005041861A3 Anhydrous silver dihydrogen citrate compositions
10/27/2005WO2005034848A3 Inhibitors of cathepsin s
10/27/2005WO2005027852A3 Compositions of polyacids and polyethers and methods for their use in reducing pain
10/27/2005WO2005009374A3 Ceramide dependent-stabilization of bace1
10/27/2005WO2005007103A3 Use of parthenolide derivatives as antileukemic and cytotoxic agents
10/27/2005WO2004100890A3 Rage g82s-related methods and compositions for treating inflammatory disorders
10/27/2005WO2004093821A3 Treatment of anthrax infection using inhibitors of lethal factor protease activity
10/27/2005WO2004075854A3 Microbicidal compositions and method of use
10/27/2005WO2004073648A3 Composition and methods for inhibiting cell survival
10/27/2005WO2004069144A3 Method for decreasing nicotine and other substance use in humans
10/27/2005WO2004064760A3 Aptamer therapeutics useful in ocular pharmacotherapy
10/27/2005US20050240253 Systems and methods for altering vestibular biology
10/27/2005US20050240021 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
10/27/2005US20050239901 Drugs; therapy for kidney diseases; removal of bile acid; gastrointestinal disorders; core-shell polymer
10/27/2005US20050239840 Benzothiophenes, formulations containing same, and methods
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239708 Use of factor VIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
10/27/2005US20050239690 Intermediate for preparing glycopeptide derivatives
10/27/2005US20050238718 Modified-release tablet of bupropion hydrochloride
10/27/2005US20050235433 Composition for dyeing keratin fibers with a cationic direct dye and a thickening polymer
10/27/2005DE29924825U1 Zusammensetzung zum Färben für Keratinfasern mit einem kationischen Direktfarbstoff und einem Silicon Dye composition for keratin fibers, comprising a cationic direct dye and a silicone
10/27/2005CA2563010A1 Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-1-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
10/26/2005EP1588702A1 Azalide antibiotics for the topical treatment or prevention of ocular infections
10/26/2005EP1588167A2 Sperm specific lysozyme-like proteins
10/26/2005EP1587951A2 Substrate detection assay
10/26/2005EP1587924A2 Methods for site-directed mutagenesis and targeted randomization
10/26/2005EP1587923A2 Improved constructs for expressing lysosomal polypeptides
10/26/2005EP1587838A2 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
10/26/2005EP1587834A2 Uses of mammalian cytokine; related reagents
10/26/2005EP1587821A2 Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
10/26/2005EP1587818A2 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
10/26/2005EP1587798A2 Geminally di-substituted nsaid derivatives as abeta 42 lowering agents
10/26/2005EP1587790A2 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
10/26/2005EP1587783A2 Cycloalkyl containing anilide ligands for the thyroid receptor
10/26/2005EP1587535A2 Title of the invention n-cyclohexylaminocarbonyl benzenesulfonamide derivatives
10/26/2005EP1587530A2 The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
10/26/2005EP1587528A2 Methods of treating and/or preventing autoimmune diseases
10/26/2005EP1587525A2 Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
10/26/2005EP1587524A2 Compositions and methods for targeted biological delivery of molecular carriers
10/26/2005EP1587513A2 Antineoplastic ether lipid compounds with modifications at the sn-2 carbon
10/26/2005EP1587483A2 Methods for modulating an inflammatory response
10/26/2005EP1587482A2 Anti-inflammatory compositions and uses thereof
1 ... 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 ... 295